BioCatalystWatch
NGENWorkspace / NGEN / OverviewCompany library
NERVGEN PHARMA CORP. logo

NERVGEN PHARMA CORP.

NERVGEN PHARMA CORP. (NGEN)

Website

Price
Market cap
Next catalystExpected 2H 2027NVG-291 — RESTORE · Enrollment completionCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

NVG-291

PTPσ

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

NVG-291

PTPσ

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

NVG-291

PTPσ

NVG-291

PTPσ

NVG-291

PTPσ

NVG-291

PTPσ

PreINDP1P2P3FilingApproved
NVG-300

PreINDP1P2P3FilingApproved

History / paused

NVG-291

PTPσ

PreINDP1P2P3FilingApproved
NVG-291

PTPσ

PreINDP1P2P3FilingApproved
NVG-291

PTPσ

PreINDP1P2P3FilingApproved
NVG-300

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

NGEN PR & News

PR & News

NGEN SEC archive